Optimising Adoptive T Cell Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation

Ghorashian, Sara; Wright, Graham; Thomas, Sharyn; Hart, Daniel P.; King, Judy; Voisine, Cecile; Pospori, Constandina; Perro, Mario; Cesco-Gaspere, Michela; Holler, Angelika; Gao, Liquan; Xue, Shao-An; Morris, Emma C.; Chakraverty, Ronjon; Stuass, Hans J.

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is carried out to correct genetic disorders of the hematopoietic system, as well as to treat hematopoietic malignancies. Adoptive Tcell therapy has great potential as an adjunct to this treatment modality, and clinical trials have already demonstrated the feasibility and efficacy of this approach. It offers two therapeutic effects in this setting:
(1) Augmentation of anti-tumor responses, such as in the setting of relapsed disease; (2) Prevention and treatment of transplant-related infections.
Underlying the therapeutic efficacy of adoptive T cell therapy is the demonstration of a graft-vs-leukemia/lymphoma (GvL) effect

• Acceptance Date: May 5, 2009
• Online Publication Date: May 1, 2015
• Publication Date: Jan 1, 2010
• Deposit Date: May 4, 2020
• Pages: 373-395
• Book Title: Bone Marrow Transplantation Across Major Genetic Barriers
• DOI: https://doi.org/10.1142/9789814271271_0016
• Public URL: http://researchrepository.napier.ac.uk/Output/2658343
• Publisher URL: https://www.worldscientific.com/doi/abs/10.1142/9789814271271_0016